Papageorgiou, Konstantinos V.
Michailidou, Margarita
Grivas, Ioannis
Petridou, Evanthia
Stamelou, Efthymia
Efraimidis, Konstantinos
Chen, Lei
Drew, Trevor W.
Kritas, Spyridon K. http://orcid.org/0000-0002-3540-9928
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 21 March 2022
Accepted: 17 May 2022
First Online: 22 June 2022
Declarations
:
: This study was performed through Research Committee of AUT (project 97128/ 19.06.2018) under the experimental protocol licence 356176/3479 (08.09.2016) provided by Veterinary General Directorate of District of Central Macedonia, Greece and vaccine import licence provided by Greek National Administration for Medicines (78230/20.07.2018). It met the standards of the International Guiding Principles for Medical Research Involving Animals and the standards of the Directive 2010/63/EU of the European Parliament and of the Council on the protection of animals used for scientific purposes. The Chinese strain of SuHV1, HeN1, was imported to the UK by Animal & Plant Health Agency (APHA), UK under Licence AHZ/2074C/2004/8 and its use is covered by a Material Transfer Agreement (tripartite agreement between the donor, the Harbin Veterinary Research Institute, and the recipients of the strain namely APHA and AUT).
: The authors declare that they have no competing interests.